Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism
Amanda Eaton; Robert J. Edwards; Gregory D. Sempowski; Kenneth Cronin; Robert Parks; Katayoun Mansouri; Maggie Barr; Lorenza Bellusci; Surender Khurana; S. Munir Alam; David C. Montefiori; Kevin O. Saunders; Barton F. Haynes.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-497634
SARS-CoV-2 Omicron variants have generated a world-wide health crisis due to resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of antibodies induced by vaccination. Here, we describe the SARS-CoV-2 neutralizing SP1-77 antibody that was generated from a humanized mouse model with a single human VH1-2 and V{kappa}1-33-associated with immensely diverse complementarity-determining-region-3 (CDR3) sequences. SP1-77 potently and broadly neutralizes SARS-CoV-2 variants of concern and binds the SARS-CoV-2 spike protein receptor-binding-domain (RBD) via a novel-CDR3-based mode. SP1-77 does not block RBD-binding to the ACE2-receptor or endocytosis step of viral entry, but rather blocks membrane fusion. Our findings provide the first mechanistic insight into how a non-ACE2 blocking antibody potently neutralizes SARS-CoV-2, which may inform strategies for designing vaccines that robustly neutralize current and future SARS-CoV-2 variants.
Texto completo
Documentos relacionados